GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 112.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 12,586.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET EARLY CALL: FTSE To Start 2021 Higher Amid Vaccine Boost

Mon, 04th Jan 2021 06:58

(Alliance News) - Stock prices in London are seen opening higher on Monday, with investors optimistic that vaccine rollouts in 2021 could spell an end to lockdown measures that battered the global economy in 2020.

IG futures indicate the FTSE 100 index is to open 29.5 points higher at 6,490.02. The blue-chip index closed down 95.30 points, or 1.5%, at 6,460.52 on Thursday.

In 2020, the FTSE 100 lost 15%, its worst annual performance since 2008.

"Investors wasted little time getting their New Year mojo on and are flying right out of gates this morning amid optimism that widespread vaccine distribution will provide the ultimate economic kick start offering a massive booster shot to corporate profits," Axi analyst Stephen Innes said.

"So far investors opt to ignore the bureaucratic treacle in Washington that threatens to gum up the works, and surging Covid case counts as more lockdowns have returned."

In the UK, the first doses of the Oxford University and AstraZeneca vaccine are set to be administered in what has been described as a "pivotal moment" in the UK's fight against coronavirus by the Health Secretary.

Just over half a million doses of the newly approved vaccine will be available from Monday, with vulnerable groups already identified as the priority for immunisation.

However, a new national lockdown looks likely to be imposed across England as the government was accused by the opposition Labour party of letting coronavirus "get out of control".

As events developed rapidly, the Daily Mail reported the government's key "Covid-O" committee that oversees restrictions was expected to meet on Monday to decide changes to the coronavirus regime.

The newspaper quoted a government source as saying ministers were looking at putting even more areas of England into the toughest Tier 4, which already covers a total of 44 million people – or 78% of the population – after changes which came into effect on Thursday.

Plans for a return of shielding for vulnerable people in England are being drawn up by the government, the Daily Telegraph reported.

After UK Prime Minister Boris Johnson signalled tougher restrictions would be brought in within weeks, pressure mounted on the government to act far more swiftly as Labour demanded a lockdown within hours.

"The health crisis is still very much in focus. Covid-19 case numbers have risen in the UK and case number in other European nations are at worrying levels too. There is talk that England is in for even tougher restrictions and there are fears that other countries, such as Germany, Denmark and Ireland will extend their lockdowns. The new strain of the coronavirus is likely to be in the headlines in the near-term but then again so is the vaccine," CMC Markets UK analyst David Madden commented.

The pound was quoted at USD1.3684 on Monday morning in London, improved from USD1.3656 at the early London equities close on Thursday. The euro stood at USD1.2251, down from USD1.2273.

Against the yen, the dollar was trading at JPY103.00, down from JPY103.06 at the London stock market close on Thursday.

In the US on New Year's Eve, Wall Street ended in the green, with the Dow Jones Industrial Average, climbing 0.7%, the S&P 500 0.6% and the Nasdaq Composite 0.1%.

The Dow and S&P 500 finished at fresh records, capping a year in which they, along with the Nasdaq, scored significant gains even amid elevated joblessness and acute pain in sectors such as hospitality, airlines, oil and gas and the performing arts.

Attention in the US will now turn to Georgia and the state's two runoff elections on Tuesday which will decide which party controls the Senate.

OANDA analyst Jeffrey Halley said: "The US state of Georgia's double-senate runoff election tomorrow looms as the week's critical event risk. The result will determine whether the Republicans or Democrats will control the Senate, with the Democrats needing to win both seats. The result will have profound implications for the United States."

"A win by the Democrats will leave them in control of all three legislative bodies and potentially an unfettered legislative path. If the Republican's win just one seat, they will control the Senate and will almost certainly make the incoming President Biden's life as difficult as possible. That almost certainly means no more fiscal stimulus and imperil any other initiatives that President Biden wishes to make."

Monday's economic calendar has a raft of manufacturing PMIs, including readings from the UK at 0930 GMT and the EU at 0900 GMT before the US at 1445 GMT.

China's manufacturing sector continued to improve in December, albeit at the slowest rate in three months, figures from Caixin showed on Monday.

The headline seasonally adjusted purchasing managers' index slipped to 53.0 points, still above the 50.0 no-change mark, but down from 54.9 in November and 53.6 in October.

The Japanese manufacturing sector ended 2020 with operating conditions stabilising in December.

The headline au Jibun Bank Japan manufacturing purchasing managers' index rose to the 50.0 no-change threshold in December from 49.0 in November.

Tokyo's Nikkei 225 closed 0.7% lower on Monday. The Shanghai Composite was 1.0% higher in late trade while Hong Kong's Hang Seng was up 0.8%.

An ounce of gold fetched USD1,923.74 on Monday morning, up from USD1,894.00 at the London equities close on Thursday.

Brent oil was quoted at USD53.04 a barrel, up from USD51.10 at the London equities close Thursday.

Members of the OPEC group of oil producers and their partners will meet via videoconference on Monday to decide on production levels for February, hoping to turn the corner on a difficult year.

The OPEC+ ministerial meeting comes after oil consumption tanked in 2020 due to the Covid-19 pandemic and a price war between Saudi Arabia and Russia.

Despite a pickup in prices towards the end of last year, the market levels for black gold remain uncertain.

By Eric Cunha; ericcunha@alliancenews.com;

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
Today 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.